GRFS logo

Grifols, S.A.

GRFS
Healthcare|Drug Manufacturers - General|ES
$8.43
-0.03 (-0.35%)
DCF Value
$17.65
Tangible Book / Share
$12.11
Graham Number
$11.70
Cash / Share
$1.02

About

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.

Stock Price

+0.8%(1Y)
1M
+13.8%
3M
+6.2%
6M
+4.1%
YTD
-9.8%
1Y
-2.0%
3Y
-7.7%
5Y
-32.6%

Pipeline Summary

32 total trials
1
Phase 1
15
Phase 2
16
Phase 3
3
Phase 4
Completed: 26Terminated: 4Withdrawn: 2

Key Facts

Market Cap$7.13B
Employees25,247
CEOJose Ignacio Abia Buenache
IPO DateJun 2, 2011
Beta1.19
52-Week Range$6.96 – $9.77
Avg Volume631,883
ExchangeNASDAQ

Ownership

Float98.7%
Shares Outstanding846.0M

Peers

ABTAbbott Laboratories
$190.22B
ADMAADMA Biologics, Inc.
$2.85B
BDXBecton, Dickinson and Company
$57.71B
BIOBio-Rad Laboratories, Inc.
$10.25B
HAEHaemonetics Corporation
$5.46B
MRVIMaravai LifeSciences Holdings, Inc.
$1.12B
QDELQuidelOrtho Corporation
$733.8M
TECHBio-Techne Corporation
$11.43B
Data last updated: Nov 9, 2026, 04:12 AM